Shanghai Novamab Biopharmaceuticals
PrivateLast Round
Series B
Extension
Jul 31, 2024
Total Funding Raised
$66.02M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Shanghai Novamab Biopharmaceuticals operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series B Extension round in July 2024.
Shanghai Novamab Biopharmaceuticals is a biopharmaceutical company that develops innovative VHH antibody (nanobody) drugs for respiratory and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Shanghai Novamab Biopharmaceuticals Comparables
Compare Shanghai Novamab Biopharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TrueLab Biopharmaceutical | 76% | |
| Sanofi | 74% | |
| Mabgeek Biotechnology | 73% |
For institutional investors. Book with your work email.
Shanghai Novamab Biopharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jul 31, 2024 | ||||
| Series B | Dec 18, 2023 | ||||
| Series A Extension | Apr 8, 2021 | ||||
| Series A | Mar 12, 2021 | ||||
| Angel | May 13, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Shanghai Novamab Biopharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Puhua Capital | Angel |
| Qiming Venture Partners | Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors increased 365% MoM.
- May 15, 2026
Monthly visitors increased 178% MoM.
For institutional investors. Book with your work email.
Shanghai Novamab Biopharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Shanghai Novamab Biopharmaceuticals's valuation, stock price, and market status.
Is Shanghai Novamab Biopharmaceuticals a public or private company?
Shanghai Novamab Biopharmaceuticals is a private company.
What is the current stock price of Shanghai Novamab Biopharmaceuticals?
Shanghai Novamab Biopharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Shanghai Novamab Biopharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Shanghai Novamab Biopharmaceuticals worth (valuation)?
Valuation information for Shanghai Novamab Biopharmaceuticals is not publicly available.
Can I buy Shanghai Novamab Biopharmaceuticals stock?
Shanghai Novamab Biopharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Shanghai Novamab Biopharmaceuticals's last funding round?
Shanghai Novamab Biopharmaceuticals's most recent funding round was Series B Extension on July 31, 2024.
Who are the main investors in Shanghai Novamab Biopharmaceuticals?
Key investors in Shanghai Novamab Biopharmaceuticals include Qiming Venture Partners.
Will Shanghai Novamab Biopharmaceuticals IPO soon?
No public IPO plans have been announced for Shanghai Novamab Biopharmaceuticals.
How can I track Shanghai Novamab Biopharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Shanghai Novamab Biopharmaceuticals's shares on secondary markets.